THE AMERICA ONE NEWS
Jun 22, 2025 |
0
| Remer,MNSponsor: QWIKET
Sponsor: QWIKET
Sponsor: QWIKET: Sports Knowledge
Sponsor: QWIKET: Elevate your fantasy game! Interactive Sports Knowledge.
Sponsor: QWIKET: Elevate your fantasy game! Interactive Sports Knowledge and Reasoning Support for Fantasy Sports and Betting Enthusiasts.
topic
America One News
20 Feb 2025
#politics
GB News: 'Liberals have reason to cry!' Michael Knowles says 'corrupt political order is coming to an end' after JD Vance speech
Michael Knowles asserts that "liberal elites" at the Munich Security Conference had reason to be upset, claiming their political influence is waning. He praised Vice-President JD Vance's speech, comparing it to Reagan's famous address, as a call to confront European leaders over issues like media censorship and suppression of free speech.
Vance criticized European leadership for failing to uphold democratic values and suggested that Europe's greatest threats are internal rather than external. He emphasized a shift in political sentiment among Europeans, pointing to recent elections of right-wing leaders as evidence of a push against the liberal status quo.
#foreignaffairs
Le Monde: After Trump's attacks on Zelensky, Europeans seek to influence upcoming negotiations
Emmanuel Macron is set to visit Washington to influence Ukraine negotiations amid concerns over U.S.-Russia talks. Donald Trump criticized Ukrainian President Zelensky, calling him a "dictator without elections," raising eyebrows among European leaders about Trump's approach to peace discussions.
Macron emphasized the importance of including Ukraine in peace talks and respecting its rights, while also addressing European security concerns during a recent videoconference with European states and Canada.
#health
Fox News: Two Alzheimer’s drugs help patients live independently at home for longer periods
Recent research indicates that two Alzheimer’s drugs, lecanemab and donanemab, can extend the period patients live independently at home. Patients treated with lecanemab could live independently for an additional 10 months, while donanemab offered 8 more months.
However, these medications come with risks and are only effective for those in the early stages of Alzheimer's. Experts emphasize the importance of discussing potential benefits and significant side effects with healthcare providers before starting treatment.